Children's National Health System Granted $3 Million in Research Funding by Mallinckrodt Pharmaceuticals

Donnerstag, 13.10.2016 22:30 von

PR Newswire

CHESTERFIELD, United Kingdom, Oct. 13, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has awarded a $3 million Healthcare Advancement Grant to Children's National Health System, the only exclusive provider of pediatric care in the Washington, DC, area, supporting a three-year outcomes research initiative focused on pediatric patients in the intensive care setting.

Mallinckrodt logo

In the U.S., 20 percent of hospitalized children are cared for in the pediatric intensive care unit (ICU). Yet this is an under-researched patient population with layers of complexity. These patients face a 2.5 to 5 percent mortality rate, with 5 to 10 percent serious morbidity rate, and the morbidity and mortality rates double within three years.

Children's National is uniquely qualified to address this opportunity, with its level IV neonatal ICU, ranked third in the nation by U.S. News and World Report in its 2016-2017 Best Children's Hospitals survey. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top National Institute of Health (NIH)-funded pediatric institutions. It is a member of the Collaborative Pediatric Critical Care Research Network of the NIH and enjoys strong partnerships with major universities in the Washington, DC, area, providing data-generation resources. The institution plans to mine data from this myriad of sources and more to unearth knowledge and improve outcomes.

"Mallinckrodt and Children's National are well aligned on the importance of research, and we are very pleased to have this exceptional opportunity to fund this crucial research initiative," said Steven Romano, M.D., Senior Vice President and Chief Scientific Officer. "We have a strong strategic focus on meeting the needs of underserved patient populations – with particular emphasis on infants – and expect the insights potentially gained from this robust research program could dramatically influence the treatment paradigm for this often-fragile pediatric patient population."

Children's National has identified three priorities to launch and execute this multi-year initiative, specifically:

  • Establish a Critical Care Outcomes Research Initiative team
  • Build on existing partnerships and expand to acquire additional data
  • Build outcomes research studies in the critical care arena

"We applaud Mallinckrodt for their forward thinking as we begin this important research initiative that will help meet the challenges faced by seriously ill pediatric patients," said Robin Steinhorn, M.D., Executive Vice President for the Center for Hospital-Based Specialties. "We firmly believe the combination of this generous research grant, our many collaborative relationships and Children's National's renowned research enterprise will lead to improved outcomes for children in the future."

About Mallinckrodt
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.  

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com

Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com

Media
Rhonda Sciarra
Senior Communications Manager
314-654-8618
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Senior Vice President, Communications and Public Affairs
314-654-3318
meredith.fischer@mallinckrodt.com

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/childrens-national-health-system-granted-3-million-in-research-funding-by-mallinckrodt-pharmaceuticals-300344576.html

SOURCE Mallinckrodt plc